Ribavirin does not impact health-related quality of life (HRQOL) in patients on Ombitasvir/ Paritaprevir /Ritonavir and dasabuvir at the end of 12-week treatment in Treatment-NaÏve adults with Genotype 1A (GT1A) Chronic Hepatitis C
Abstract
Authors
Y. Liu D. Bernstein L. Larsen Y. Luo Y. Xie T. Juday